Three Cannabis Biopharmaceutical Companies for Your Portfolio

The cannabis biotechnology sector consists of pharmaceutical companies that are actively pursuing the research and development of new medicines utilizing cannabinoids and cannabinoid receptors. The sector is expected to continue to grow as additional universities, companies, and governments expand their research into cannabinoids, the endocannabinoid system and medicinal cannabis products.

GW Pharmaceuticals (NASDAQ:GWPH)

United Kingdom-based GW Pharmaceuticals created the first cannabis-derived medicine to gain market approval: Sativex, a multiple sclerosis treatment. In June 2018 the FDA approved another cannabis-derived medicine made by GW: Epidolex. The cannabidiol (CBD) based drug has been approved for the treatment of seizures associated with two rare and severe forms of epilepsy (Lennox-Gastaut syndrome and Dravet syndrome) in the United States.

The company is looking toward European regulatory approval for Epidolex in 2019. Analysts have estimated that the drug could reach $1-2 billion in annual sales. GW also has a pipeline of early-stage cannabinoid-derived medicines that are in development. These drugs target diseases like epilepsy, autism spectrum disorders, glioblastoma, and schizophrenia.

AXIM Biotechnologies Inc. (OTC:AXIM)

New York-based AXIM Biotechnologies is a global leader in the research and development of cannabinoid-derived pharmaceutical products. The company has been issued 5 patents and has 12 more currently filed. AXIM also has a solid 28 trademarks in its Intellectual Property Portfolio.

The company has six cannabinoid-based drugs which are currently making their way through 16 different research experiments (in stages ranging from preclinical to phase 1 & 2 of clinical trials). The drugs are geared towards treating a range of maladies from opiod addiction to inflammatory bowel disease to dry eyes and smoking cessation. AXIM is trying a series of different delivery methods for its cannabinoid based products including via chewing gum, capsules, topical methods, eye drops and even a suppository for those afflicted with inflammatory bowel disease.

InMed Pharmaceuticals (CSE:IN)

Vancouver, Canada-based InMed Pharmaceuticals is a pre-clinical biopharmaceutical company that specializes in the discovery and development of new cannabis-derived medicines and therapeutics for the treatment of diseases which have a high unmet medical need. The company also utilizes innovative drug delivery systems. InMed has negative earnings but despite this, the company has solid proprietary cannabinoid biosynthesis technology and a strong drug development pipeline.

Instead of using a “brute-force attack” method when fighting diseases InMed has developed a proprietary bioinformatics assessment device. This technology allows the company to pinpoint individual cannabis strains that have a greater therapeutic effect on certain diseases. The system uses a computer-based drug selection process to derive conclusions from massive public datasets coupled with the company’s internal library of cannabinoid information.

InMed’s main product is INM-750, a cannabinoid medicine applied topically to treat epidermolysis bullosa. The company is also in the midst of developing INM-085, a cannabinoid therapy for glaucoma, and INM-405, a cannabis-derived treatment for orofacial pain.

CEO Eric Adams recently announced the addition of Dr. Steven M. Dinh to InMed’s Scientific Advisory Board. Dr. Dinh has over 30 years of pharmaceutical and biotech executive leadership experience. He is a Fellow of the American Association of Pharmaceutical Scientists, and a Fellow of the American Institute for Medical and Biological Engineering. Dr. Dinh was quoted saying he’s “sincerely impressed with InMed’s science-rich R&D pipeline and platform…[and] believe InMed’s cannabinoid-focused scientific approach is novel, differentiated and promising.”

Featured image courtesy of Shutterstock.